Dacarbazine Resistance in Melanoma Driven by Pdcd4 Downregulation and Cell Cycle Dysregulation

Patients with advanced metastatic melanoma face poor prognoses due to low response rates to anticancer agents. A significant challenge is resistance to dacarbazine (DTIC), a key chemotherapy drug. This resistance often leads to treatment failure and unfavorable outcomes. Researchers are exploring novel targets to overcome this, focusing on programmed cell death 4 (Pdcd4), a tumor suppressor gene. While Pdcd4 is known to influence cell cycle regulation in various cancers, its precise role in DTIC resistance and the underlying mechanisms remain largely undefined.

Researchers established DTIC-resistant mouse melanoma cells to investigate the mechanisms of acquired drug resistance. They measured cell proliferation to confirm resistance acquisition. To elucidate the resistance mechanism, key cell cycle regulatory factors were analyzed using western blotting and flow cytometry. The study specifically examined the relationship between Pdcd4 expression levels and alterations in cell cycle progression in these resistant cells compared to non-resistant controls.

DTIC-resistant melanoma cells displayed significantly decreased Pdcd4 protein levels compared to non-resistant cells. This downregulation correlated with notable changes in cell cycle regulators: expression of Cyclin D1 (a G1 phase regulator) and Cyclin E (involved in S-phase progression) was significantly increased. Additionally, expression of p21, a CDK inhibitor, also increased in resistant cells. Flow cytometric analysis revealed that while DTIC treatment typically reduces the S-phase population in non-resistant cells, this effect was absent in resistant cells.

Cyclin D1 expression remained elevated in resistant cells even after extended culture in the absence of DTIC, suggesting a stable, intrinsic dysregulation contributing to resistance.